Oncoquest Inc., of Edmonton, Alberta, presented preclinical data from its IgE-based immunotherapy platform at the Society for Immunotherapy of Cancer meeting in National Harbor, Md., demonstrating the generation of an antigen-specific immunity that protected against pancreatic cancer in a transgenic animal tumor model using combinatory immunotherapy with that class of antibodies.